A Quote by Kallam Anji Reddy

To start with, pharma was an industry based on innovation, drug discovery. — © Kallam Anji Reddy
To start with, pharma was an industry based on innovation, drug discovery.
I am attached to an incredible script called 'Wonder Drug,' about the DES drug disaster. It's a female-based drama, and I am so proud to be a part of because hopefully it will help evoke change - not only in our industry, but in the battle again corruption in big pharma.
The pharma industry is one of the few industries that comes up every year and brags about how much worse they got - like, now it costs $2 billion to make a drug, and it was a billion 5 years ago.
We've got to get our drug industry back. Our drug industry has been disastrous. They're leaving left and right. They supply our drugs, but they don't make them here, to a large extent. And the other thing we have to do is create new bidding procedures for the drug industry because they're getting away with murder.
If you look across the economy, if you have multiple players in an industry, you have more customization, more innovation, greater choice for consumers. The more you have consolidation, the less likely you are to invest in innovation. It becomes all about driving down cost and mass production. And that's not good for innovation in an industry.
The beauty industry is always led by innovation. When you think about over the past three or four years, some of the best innovation in our industry has come from Korea.
While many have been left behind by Part D, there is a clear winner: the drug industry. Independent analysts predict that Part D will increase drug industry profits by $139 billion over the next eight years. Glaxo-SmithKline's second-quarter net income already jumped 14 percent, and other leading drug companies also have benefited.
I think, particularly in our tech industry, this is an industry that has violent innovation and then commoditization, and it's a cycle of innovation/commoditization.
Drug company payments to doctors are a small part of a much larger strategy by Big Pharma to clean our pockets.
Sustainable solutions based on innovation can create a more resilient world only if that innovation is focused on the health and well-being of its inhabitants. And it is at that point - where technology and human needs intersect - that we will find meaningful innovation.
Intellectual-property rules are clearly necessary to spur innovation: if every invention could be stolen, or every new drug immediately copied, few people would invest in innovation. But too much protection can strangle competition and can limit what economists call 'incremental innovation' - innovations that build, in some way, on others.
Financial risk is always associated with drug discovery. But the benefit that a blockbuster drug can bring to the business can be phenomenal if you can take that risk.
Drug discovery is terribly expensive, just to find out how one drug could or could not work and all its side effects.
If tomorrow the Chinese decide not to supply the world with raw materials, the pharma industry would collapse.
For all of life's discontents, according to the pharmaceutical industry, there is a drug and you should take it. Then for the side effects of that drug, then there's another drug, and so on. So we're all taking more drugs, and more expensive drugs.
Indians have very good engineering capabilities, and that is why, if an industry focuses on innovation, you will have a far greater chance of success, rather than the model which is based on just being a production machine.
In pharma or in information, you have to invest for three or four years, and then you start seeing returns.
This site uses cookies to ensure you get the best experience. More info...
Got it!